Jason Lockrow

Jason Lockrow

Auto-generated profile, based on publicly available information

Jason Lockrow

Department of Neurology Seattle Children's Hospital, University of Washington Seattle Washington USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Seminars in Pediatric Neurology
Verified
Journal Article
Closed access
CBChristopher W. Beatty
Christopher W. Beatty
JLJason P. Lockrow
Jason P. Lockrow
SGSatyanarayana Gedela
Satyanarayana Gedela
AGAlison Paige Gehred
Alison Paige Gehred
AOAdam P. Ostendorf
Adam P. Ostendorf

19 January 2022 in Journal of Child Neurology
Verified
Journal Article
Closed access
KKKelly G. Knupp
Kelly G. Knupp
JCJason Coryell
Jason Coryell
RSRani K. Singh
Rani K. Singh
WGWilliam D. Gaillard
William D. Gaillard
RSRenée A. Shellhaas
Renée A. Shellhaas
EJElizabeth Juarez-Colunga
Elizabeth Juarez-Colunga
Objective: In a randomized trial, we aimed to evaluate the efficacy of cosyntropin injectable suspension, 1 mg/mL, compared to vigabatrin for infantile spasms syndrome. An additional arm was included to assess the efficacy of combination therapy (cosyntropin and vigabatrin) compared with cosyntropin monotherapy. Methods: Children (2 months to 2 years) with new-onset infantile spasms syndrome and hypsarhythmia were randomized into 3 arms: cosyntropin, vigabatrin, and cosyntropin and vigabatrin combined. Daily seizures and adverse events were recorded, and EEG was repeated at day 14 to assess for resolution of hypsarhythmia. The primary outcome measure was the composite of resolution of hypsarhythmia and absence of clinical spasms at day 14. Fisher exact test was used to compare outcomes. Results: 37 children were enrolled and 34 were included in the final efficacy analysis (1 withdrew prior to treatment and 2 did not return seizure diaries). Resolution of both hypsarhythmia and clinical spasms was achieved in in 9 of 12 participants (75%) treated with cosyntropin, 1/9 (11%) vigabatrin, and 5/13 (38%) cosyntropin and vigabatrin combined. The primary comparison of cosyntropin versus vigabatrin was significant (64% [95% confidence interval 21, 82], P < .01). Adverse events were reported in all 3 treatment arms: 31 (86%) had an adverse event, 7 (19%) had a serious adverse event, and 15 (42%) had an adverse event of special interest with no difference between treatment arms. Significance: This randomized trial was underpowered because of incomplete enrollment, yet it demonstrated that cosyntropin was more effective for short-term outcomes than vigabatrin as initial treatment for infantile spasms.

1 January 2019 in Epilepsy & Behavior Case Reports
Verified
Journal Article
Open access
JLJason Lockrow
Jason Lockrow
HTHannah Tully
Hannah Tully
RSRussell P. Saneto
Russell P. Saneto
Congenital TORCH infections are a significant cause of epileptic spasms, an infantile epileptic encephalopathy, through disruptions to several pathways in neurodevelopment. Congenital Zika virus has a similar neurotropism to other TORCH agents, and leads to microcephaly, severe neurodevelopmental impairment, and high rates of early onset seizures. Here we report a child with confirmed congenital Zika virus who developed extensor epileptic spasms and hypsarrhythmia associated with a loss of early developmental milestones. Early treatment led to resolution of epileptic spasms and improved developmental trajectory, though the child continues to have ongoing focal seizures and prominent developmental impairment. Congenital Zika virus infection requires close monitoring as early identification of epileptic spasms is likely important in long term developmental outcome.

24 July 2019 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
JLJason P. Lockrow
Jason P. Lockrow
JWJason N. Wright
Jason N. Wright
RSRussell P. Saneto
Russell P. Saneto
CACatherine Amlie-Lefond
Catherine Amlie-Lefond
Perinatal stroke is a significant cause of severe epilepsy, including epileptic spasms. Although epileptic spasms due to underlying structural lesion often respond poorly to treatment and evolve into drug-resistant epilepsy, outcomes are not uniformly poor, and predictors of outcomes are not well described. We performed a single-institution retrospective review of epileptic spasms following perinatal stroke to determine if outcome depended on vascular subtype. We identified 24 children with epileptic spasms due to perinatal ischemic stroke: 11 cases of perinatal arterial stroke and 13 cases of perinatal venous infarct. Initial response to treatment was similar between groups; however, although children with perinatal arterial stroke who responded to epileptic spasms therapy had high rates of seizure freedom, many children with perinatal venous infarct, regardless of initial response, had residual drug-resistant epilepsy. We consider whether the mechanism for epileptogenesis may be different between arterial and venous strokes, and whether these 2 groups should be monitored for epileptic spasms, and subsequent epilepsy, differently.

19 July 2025 in Epilepsia
Verified
Journal Article
Closed access
KHKoko Hall
Koko Hall
RSRussell Saneto
Russell Saneto
SRStephanie Randle
Stephanie Randle
MWMark Wainwright
Mark Wainwright
PBPatricia Berry
Patricia Berry
JHJason S. Hauptman
Jason S. Hauptman